摘要
目的探讨三拗汤联合沙丁胺醇对咳嗽变异型哮喘患者的临床疗效。方法80例患者随机分为对照组和观察组,每组40例,对照组给予沙丁胺醇治疗,观察组在对照组基础上加用三拗汤,疗程3个月。检测临床疗效、EOS、SIgG4、TIgE、Eotaxin、NKA、LTD4、IL-27、SP、R5-R20、Fres、R5、Zrs、PEF昼夜变异率、FEF25、PEF、ACT评分、PAQLQ评分、复发率、不良反应发生率变化。结果观察组总有效率高于对照组(P<0.05),复发率更低(P<0.05)。治疗后,2组EOS、TIgE、Eotaxin、NKA、LTD4、SP、R5-R20、Fres、R5、Zrs、PEF昼夜变异率降低(P<0.05),SIgG4、IL-27、FEF25、PEF、ACT评分、PAQLQ评分升高(P<0.05),以观察组更明显(P<0.05)。2组不良反应发生率比较,差异无统计学意义(P<0.05)。结论三拗汤联合沙丁胺醇可安全有效地改善咳嗽变异型哮喘患者EOS、TIgE、Eotaxin、SIgG4水平及气道阻力指标、肺功能指标,调节神经源性介质,缓解气道炎症损伤,提高生活质量,减少复发率。
AIM To explore the clinical effects of San’ao Decoction combined with salbutamol on patients with cough variant asthma.METHODS Eighty patients were randomly assigned into control group(40 cases)for 3-month administration of salbutamol,and observation group(40 cases)for 3-month administration of both San’ao Decoction and mifepristone.The changes in clinical efficacy,TCM syndrome scores,serum MMP-9,VEGF and sex hormones(E 2,FSH,PRL)and incidence of adverse reactions were detected.The changes in clinical efficacy,EOS,SIgG4,TIgE,Eotaxin,NKA,LTD4,IL-27,SP,R5-R20,Fres,R5,Zrs,PEF diurnal variation rate,FEF25,PEF,ACT score,PAQLQ score,recurrence rate and incidence of adverse reactions were detected.RESULTS The observation group demonstrated higher total effective rate than the control group(P<0.05),along with lower recurrence rate(P<0.05).After the treatment,the two groups displayed decreased EOS,TIgE,Eotaxin,NKA,LTD4,SP,R5-R20,Fres,R5,Zrs and PEF diurnal variation rate(P<0.05),and increased SIgG4,IL-27,FEF25,PEF,ACT score,PAQLQ score(P<0.05),especially for the observation group(P<0.05).No significant difference in incidence of adverse reactions was found between the two groups(P>0.05).CONCLUSION For the patients with cough variant asthma,San’ao Decoction combined with salbutamol can improve EOS,TIgE,Eotaxin,SIgG4 levels and airway resistance indices,lung function indices,regulate neurogenic mediators,alleviate airway inflammation injury,enhance life quality,and reduce recurrence rate.
作者
张延君
刘菊
孔祥才
金继超
白明学
ZHANG Yan-jun;LIU Ju;KONG Xiang-cai;JIN Ji-chao;BAI Ming-xue(Zhengzhou Municipal Hospital of Traditional Chinese Medicine,Zhengzhou 450003,China)
出处
《中成药》
CAS
CSCD
北大核心
2023年第12期3954-3958,共5页
Chinese Traditional Patent Medicine
基金
河南省药品监督管理局科技计划项目(2020DB140)。